cryopyrin-associated periodic syndromes

cryopyrin-associated periodic syndromes

A range of autoinflammatory disorders—e.g., familial cold autoinflammatory syndrome (FCAS, aka familial cold-induced urticaria), Muckle-Wells syndrome, and neonatal-onset multisystem inflammatory disease (NOMID, aka chronic infantile neurologic cutaneous and articular syndrome [CINCA])—which share many clinical features (e.g., fever, rash, joint pain, conjunctivitis, headaches, general malaise).

Management
Monoclonal antibodies against IL 1 beta (e.g., canakinumab), other IL-1 binding proteins (e.g., rilonacept), or IL-1 receptor antagonist (e.g., anakinra).
Mentioned in ?
References in periodicals archive ?
In addition to its approval for SJIA in the US, Ilaris is approved in more than 60 countries, including in the EU, US, Switzerland and Japan for the treatment of Cryopyrin-Associated Periodic Syndromes (CAPS), a rare, lifelong, genetic disorder with debilitating symptoms[sup.
Already approved for cryopyrin-associated periodic syndromes, the anti-inflammatory interleukin-1 inhibitors rilonacept (Arcalyst) and canakinumab (Ilaris) are being studied both for acute gout and for prophylaxis.
In vivo regulation of interleukin 1 in patients with cryopyrin-associated periodic syndromes.
Cryopyrin-Associated Periodic Syndromes (CAPS), Muckle-Wells Syndrome, Familial Cold Autoinflammatory Syndrome (FCAS)
for the treatment of children and adults with the severe form of Cryopyrin-Associated Periodic Syndromes (CAPS) called Neonatal-Onset Multisystem Inflammatory Disease (NOMID).
Rilonacept has been approved for cryopyrin-associated periodic syndromes, but is clinically effective in only a few patients with the autoinflam-matory syndrome.
Rheumatic diseases: Gout, osteoarthritis, rheumatoid arthritis, juvenile idiopathic arthritis, juvenile rheumatoid arthritis, spondyloarthropathies, ankylosing spondylitis, psoriatic arthritis, reactive arthritis, systemic lupus erythematosus, systemic sclerosis, cryopyrin-associated periodic syndromes (CAPS), familial cold auto-infl ammatory syndrome (FCAS), Muckle-Wells syndrome (MWS).
The FDA's action does not impact the approved indication of ARCALYST for the treatment of Cryopyrin-Associated Periodic Syndromes (CAPS), including Familial Cold Auto-inflammatory Syndrome (FCAS) and Muckle-Wells Syndrome (MWS) in adults and children 12 and older.
Arcalyst, approved for treating Cryopyrin-Associated Periodic Syndromes (CAPS), generated revenue of $9.
ARCALYST, an interleukin-1 (IL-1) blocker, was approved in February 2008 for the treatment of Cryopyrin-Associated Periodic Syndromes (CAPS), including Familial Cold Auto-inflammatory Syndrome (FCAS) and Muckle-Wells Syndrome (MWS) in adults and children 12 and older.
today announced it has received marketing authorization in the European Union for rilonacept, an interleukin-1 blocker, for the treatment of Cryopyrin-Associated Periodic Syndromes (CAPS) with severe symptoms, including Familial Cold Auto-inflammatory Syndrome (FCAS) and Muckle-Wells Syndrome (MWS), in adults and children aged 12 years and older.
NASDAQ:REGN) today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMEA) has issued a positive opinion for the marketing authorization in the European Union of rilonacept, an interleukin-1 blocker, for the treatment of Cryopyrin-Associated Periodic Syndromes (CAPS) with severe symptoms, including Familial Cold Auto-inflammatory Syndrome (FCAS) and Muckle-Wells Syndrome (MWS), in adults and children aged 12 years and older.